Concern over reports that link diabetes drugs to heart trouble is compelling U.S. drug regulators to ask diabetes-drug makers for more safety data. These requests for additional data could delay new product approvals by years and add millions of dollars to development and post-market commitment costs.The U.S. Food and Drug Administration is reportedly sending letters to all companies with diabetes drugs in development, informing them that the agency will now require safety data prior to approval that measures a drug's cardiovascular risk.
Diabetes-Drug Makers Face FDA Hurdle
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts